fosamprenavir has been researched along with Laryngopharyngeal Reflux in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, LA; Blumin, JH; Bock, J; Goetz, CJ; Johnston, N; MacKinnon, AC; Miller, J; Ondrey, F; Samuels, TL; Seabloom, D; Silvaggi, NR; Smith, BC; Vuksanovic, N; Wiedmann, TS; Wuertz, B | 1 |
| Blaine-Sauer, S; Johnston, N; Samuels, TL; Yan, K | 1 |
2 other study(ies) available for fosamprenavir and Laryngopharyngeal Reflux
| Article | Year |
|---|---|
Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model.
Topics: Animals; Carbamates; Furans; Laryngopharyngeal Reflux; Larynx; Mice; Pepsin A; Sulfonamides | 2023 |
The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.
Topics: Animals; Enzyme Inhibitors; Esophageal Neoplasms; Laryngopharyngeal Reflux; Mice; Pepsin A; Protease Inhibitors; Proton Pump Inhibitors; Quality of Life | 2023 |